

Newsletter

We are getting there!

After a year of hard work, it is time for an update! In February 2019, we have finalized the study protocol and obtained ethical approval from the Institutional Review Board of the Erasmus MC. Over the summer, our colleagues in the Radboud UMC in Nijmegen (The Netherlands) have also obtained their ethical approval.

This is very exciting as we are now waiting for the first eligible patient to include in the STEPS-EA trial: the first randomized controlled trial within ERNICA!

In the coming months we will further expand the active centers. Copenhagen (Denmark), Helsinki (Finland), Odense (Denmark) and Stockholm (Sweden) have submitted the study protocol to their local ethical committee. Padua (Italy), Amsterdam (The Netherlands) and Rome (Italy) only have to finalize the clinical trial agreement before also they also can apply for ethical approval. Lille (France), Paris (France), London (United Kingdom) and Marseille (France) have expressed their interest in participating in this international trial but have to overcome some logistic difficulties first.

In other words: we are getting there!

We all know the struggles of an international multicenter trial but only collaboration in projects like this enables us to do high-level research in rare diseases.

We are looking forward to the first inclusion and remain always happy to assist in any way possible!

The STEPS-EA trial team
steps.ea@erasmusmc.nl



The STEPS-EA trial: intralesional STERoid injections to Prevent refractory Strictures in patients with Esophageal Atresia
 → 1:1 randomization to injection with 10 mg/ml TAC (Kenacort-A 10) prior to balloon dilatation and balloon dilatation without any injection

Road to success



Inclusions n=0

Ready for the 1st patient!



Waiting for ethical approval



Waiting for legal department



Interested in participation

